Intercell obtains results from its first Phase I investigational vaccine study for Streptococcus pneumoniae

16-Feb-2010 - Austria

Intercell AG announced results from a Phase I clinical trial investigating the company’s vaccine candidate for the prevention of infections by the bacterium Streptococcus pneumoniae. Intercell’s investigational prophylactic vaccine candidate (IC47) is a recombinant subunit vaccine consisting of three highly conserved proteins of Streptococcus pneumoniae.

In the first-in-man trial, 32 healthy adults were vaccinated with Intercell’s investigational vaccine. Two antigen dosages, with and without addition of aluminum hydroxide, were applied in four different study groups. The initial analysis of the data has indicated a good safety and tolerability of the vaccine candidate, which was confirmed by a Data Safety Monitoring Board. The vaccine was immunogenic, and antigen dose-dependent induction of antibodies was confirmed for all three proteins of the vaccine.

“We are pleased that we have been able to generate first-in-man data for a further vaccine candidate based on antigens discovered through our Antigen Identification Program (AIP®). Subject to clearance with the authorities and our partners, we next intend to initiate clinical development in two target populations – children and the elderly,” stated Thomas Lingelbach, Intercell’s Chief Operating Officer.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous